



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/841,805	04/24/2001	Preeti Lal	PF-0456-2 DIV	7874

27904 7590 03/11/2003

INCYTE GENOMICS, INC.
3160 PORTER DRIVE
PALO ALTO, CA 94304

[REDACTED]

CARLSON, KAREN C

[REDACTED]

[REDACTED]

1653

DATE MAILED: 03/11/2003

9

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)	
	09/841,805	LAL ET AL.	
	Examiner Karen Cochrane Carlson, Ph.D.	Art Unit 1653	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on 07 November 2002.
- 2a) This action is FINAL. 2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 10 and 29-44 is/are pending in the application.
- 4a) Of the above claim(s) 29,32,34,35,38 and 44 is/are withdrawn from consideration.
- 5) Claim(s) _____ is/are allowed.
- 6) Claim(s) 10,30,31,33,36,37 and 39-42 is/are rejected.
- 7) Claim(s) _____ is/are objected to.
- 8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) The proposed drawing correction filed on _____ is: a) approved b) disapproved by the Examiner.
If approved, corrected drawings are required in reply to this Office action.
- 12) The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

- 13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) All b) Some * c) None of:
1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.
- 14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
a) The translation of the foreign language provisional application has been received.
- 15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

- | | |
|--------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) Paper No(s). _____ . |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO-1449) Paper No(s) <u>0</u> . | 6) <input type="checkbox"/> Other: _____ . |

Art Unit: 1653

Applicant's election with traverse Invention II, drawn to antibodies against human recycling proteins having SEQ ID NO; 1 or NO: 3, Claims 10, 30, 31, 33, 36, 37, and 39-42 in Paper No. 7, filed November 7, 2002, is acknowledged. The traversal is on the ground(s) that methods of using this antibody should be rejoined when the antibody product is allowed. This is found persuasive because; however, the antibody is not allowable for reasons being made of record below and therefore the inventions will remain separate.

The requirement is still deemed proper and is therefore made FINAL.

Claims 1-9, 11-28, and 45-48 have been canceled. Claims 29, 32, 34, 35, 38, 34, and 44 have been withdrawn from further consideration at this time by the Examiner because these Claims are drawn to non-elected inventions. Claims 10, 30, 31, 33, 36, 37, and 39-42 are currently under examination.

Priority is to January 8, 1998.

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 36 and 39 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. Claims 36 and 39 depend from non-elected inventions. Therefore, these claims are indefinite.

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

Art Unit: 1653

- (a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.
- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 10, 30, 31, 33, 36, 37, and 39-42 are rejected under 35 U.S.C. 102(a) as being anticipated by Singleton et al. (26 August 1997; J. Cell. Sci. 110:2099-2107).

Singleton et al. teach secretory carrier membrane protein (SCAMPs) SCAMP3 having 98.1% sequence identity to SEQ ID NO:1. See Fig. 1. At page 2101, col. 1, line 14, Singleton et al. teach making antibodies to SCAMP3 using the sequence SPTEPKNYGSYSTQ, which is found within instant SEQ ID NO: 1. Given that antibodies bind epitopic structures rather than sequences per se, and the identity between SCAPM3 and SEQ ID NO: 1 is high, the antibody made by Singleton et al. will also bind polypeptides having SEQ ID NO: 1 (Claim 10, 30, 36, 39). The antibodies were in composition (Claim 31, 37, 40), and the antibodies were labeled via coupling to hemocyanin (Claim 33). Claims 41 and 42 are being considered to be anticipated as well because there appears to be no difference in the antibody made by a Fab expression library or and immunoglobulin expression library.

Singleton et al. also teach SCAMP2 having 99% sequence identity to SEQ ID NO: 3. See Fig. 1. At page 2101, col. 1, line 12, Singleton et al. teach making antibodies to SCAMP2 using the sequence QPSVEPTOPTPO, which is found within instant SEQ ID NO: 3. Given that antibodies bind epitopic structures rather than sequences per se, and the identity between SCAPM2 and SEQ ID NO: 3 is high, the antibody made by Singleton et al. will also bind polypeptides having SEQ ID NO: 3 (Claim 10, 30, 36, 39). The antibodies were in composition (Claim 31, 37, 40), and the antibodies were labeled via coupling to hemocyanin (Claim 33). Claims 41 and 42 are being considered to be anticipated as well because there appears to be no difference in the antibody made by a Fab expression library or and immunoglobulin expression library.

Claims 10, 30, 31, 33, 36, 37, and 39-42 are rejected under 35 U.S.C. 102(b) as being anticipated by Brand et al. (1993; EMBO J. 12(10) 3753-3761).

Brand et al. teach secretory carrier membrane protein (SCAMPs) SCAMP37 having 51% sequence identity to SEQ ID NO:1. See Fig. 5a . At page 3760, col. 1, para. 1, Brand et al. teach making antibodies to SCAMP37, resulting in antibody SG7C12. Given that antibodies bind epitopic structures rather than sequences per se, and the identity between SCAMP37 and SEQ ID NO: 1 is high, the antibody made by Brand et al. will also bind polypeptides having SEQ ID NO: 1 (Claim 10, 30, 36, 39). The antibodies were in composition (Claim 31, 37, 40), and the antibodies were labeled via coupling to Affigel-Hz (para. 2; Claim 33). Claims 41 and 42 are being considered to be anticipated as well because there appears to be no difference in the antibody made by a Fab expression library or and immunoglobulin expression library.

SCAMP 37 also has 57.4% sequence identity to SEQ ID NO: 3. See Fig. 5a. At page 3760, col. 1, para. 1, Brand et al. teach making antibodies to SCAMP37, resulting in antibody SG7C12. Given that antibodies bind epitopic structures rather than sequences per se, and the identity between SCAMP37 and SEQ ID NO: 1 is high, the antibody made by Brand et al. will also bind polypeptides having SEQ ID NO: 1 (Claim 10, 30, 36, 39). The antibodies were in composition (Claim 31, 37, 40), and the antibodies were labeled via coupling to Affigel-Hz (para. 2; Claim 33). Claims 41 and 42 are being considered to be anticipated as well because there appears to be no difference in the antibody made by a Fab expression library or and immunoglobulin expression library.


Art Unit: 1653

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Karen Cochrane Carlson, Ph.D. whose telephone number is 703-308-0034. The examiner can normally be reached on 7:00 AM - 4:00 PM, off alternate Fridays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Dr. Christopher Low can be reached on 703-308-2329. The fax phone numbers for the organization where this application or proceeding is assigned are 703-308-4242 for regular communications and 703-308-4242 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-1235.

March 6, 2003

A handwritten signature in black ink, appearing to read "Karen Cochrane Carlson, Ph.D.", is positioned to the right of the typed name and address.